Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs.

After the FDA asked for more clinical data in May 2025, Moderna has decided to resubmit the BLA later this year.

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered ...

We learn how the EU’s new Clinical Trial Regulation (CTR) and the CTIS platform are reshaping clinical trial approvals and ...

Despite the boost to contributions, WHO has downsized its 2026-27 budget by over $1bn due to financial constraints.

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

The US Food and Drug Administration (FDA) is set to restrict the Covid-19 booster doses to older adults and those at risk of ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

The US Department of Health and Human Services (HHS) said it is “taking immediate steps” to implement a recent Executive ...

Companies remain exposed to heightened risks between the world’s largest markets and are cautious of the stability of ...

The 5th Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) will gather industry leaders in Vösendorf, Austria on ...

The Japanese MHLW has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations for MM.